Radioligand Therapy for Lung Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new radiation treatment for lung cancer patients who have not responded well to previous treatments. The treatment uses a drug to deliver radiation directly to the cancer cells, aiming to kill them more effectively.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot have had cytotoxic or antineoplastic therapy within 21 days of consent (42 days for certain drugs) or antibody therapy within 21 days. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the treatment 203-Lead Pentixather SPECT/CT, 212-Lead Pentixather for lung cancer?
Radioligand therapy, which includes treatments similar to 203-Lead Pentixather SPECT/CT, 212-Lead Pentixather, has shown promise in treating various cancers by targeting specific molecules in cancer cells. Alpha radioligand therapies, like those used in prostate and neuroendocrine cancers, have demonstrated high effectiveness due to their ability to deliver targeted radiation to cancer cells, suggesting potential benefits for lung cancer treatment as well.12345
What makes the treatment 212-Lead Pentixather unique for lung cancer?
212-Lead Pentixather is a type of radioligand therapy that uses alpha particles to target and destroy cancer cells with high precision, potentially offering greater effectiveness and fewer side effects compared to traditional treatments. This approach is novel because it delivers radiation directly to cancer cells, minimizing damage to surrounding healthy tissue.15678
Research Team
Yusuf Menda, MD
Principal Investigator
University of Iowa
Eligibility Criteria
This trial is for patients with atypical carcinoid lung lesions who've tried or declined other treatments. They must have a lesion ≥2 cm that's positive for CXCR4, can consent independently, and have good liver and kidney function. People with recent major surgery, other recent therapies, pregnant or breastfeeding women, those not using birth control, or with uncontrolled illnesses are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dosimetry and Imaging
Participants undergo SPECT/CT imaging with Lead-203 Pentixather and serial blood sampling for dosimetry calculations
Treatment
Participants receive up to 2 infusions of Lead-212 Pentixather, with 6 weeks between each infusion, and kidney protectant infusions
Follow-up
Participants undergo imaging at 3 months post-treatment to determine disease response
Treatment Details
Interventions
- 203-Lead Pentixather SPECT/CT
- 212-Lead Pentixather
Find a Clinic Near You
Who Is Running the Clinical Trial?
Yusuf Menda
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
National Cancer Institute (NCI)
Collaborator
Holden Comprehensive Cancer Center
Collaborator